Hydrochloric Acid → (R)-1-(2-(6-cyclopropylpyridin-2-yl)-3H-imidazo[4,5-b]pyridin-5-yl)piperidine-3-carboxylic acid

반응식

[CH:1]1([C:4]2[N:9]=[C:8]([C:10]3[NH:29][C:13]4=[N:14][C:15]([N:18]5[CH2:23][CH2:22][CH2:21][C@@H:20]([C:24]([O:26]CC)=[O:25])[CH2:19]5)=[CH:16][CH:17]=[C:12]4[N:11]=3)[CH:7]=[CH:6][CH:5]=2)[CH2:3][CH2:2]1.[OH-].[Na+].Cl>C(O)C>[CH:1]1([C:4]2[N:9]=[C:8]([C:10]3[NH:29][C:13]4=[N:14][C:15]([N:18]5[CH2:23][CH2:22][CH2:21][C@@H:20]([C:24]([OH:26])=[O:25])[CH2:19]5)=[CH:16][CH:17]=[C:12]4[N:11]=3)[CH:7]=[CH:6][CH:5]=2)[CH2:3][CH2:2]1

참가 물질

실험 절차

To a solution of (R)-ethyl 1-(2-(6-cyclopropylpyridin-2-yl)-3H-imidazo[4,5-b]pyridin-5-yl)piperidine-3-carboxylate (150 mg, 0.383 mmol) in ethanol (15 mL) was added a 2N sodium hydroxide solution (5 mL) at 0° C. The mixture was stirred at room temperature for 2 h, then was neutralized with a 2M hydrochloric acid solution and was extracted with ethyl acetate. The organic layer was dried over sodium sulfate and concentrated under reduced pressure to afford (R)-1-(2-(6-cyclopropylpyridin-2-yl)-3H-imidazo[4,5-b]pyridin-5-yl)piperidine-3-carboxylic acid (150 mg). MS (ES+APCI) (M+H) 364.2; LCMS retention time 2.974 min (Method J).